Posted on 6 April 2026
Ana joined LSTM in 2019, she leads a team which focuses on the development and evaluation of novel diagnostics for emerging viral infections and outbreak prone infectious diseases such as COVID-19, Mpox, Crimean Congo Haemorrhagic Fever (CCHF) and Rift Valley Fever (RVF).
Ana played a substantial role in the UK COVID-19 pandemic response including the leadership of the FIND-WHO diagnostic evaluations where her team recruited over 2000 participants in diagnostic trials. She is currently involved in the evaluation of Mpox diagnostics under the FIND-WHO pandemic threats umbrella, the evaluation of novel diagnostics for TB and in the development of point-of-care tests for CCHF and RVF following successful funds from MRC and LifeArc.
She is one of the Diagnostics leads within the Research Centre for Drugs and Diagnostics (RCDD) at LSTM and sits on the Scientific Advisory Group of the Liverpool Pandemic Institute.